About Team Advisors Investors News Contact

ABOUT

NetVation DL Medicine is a Chengdu, China based biopharmaceutical company dedicated to advancing novel therapeutic entities into the clinic for Metabolic, Inflammatory and Cancer related diseases. NetVation DL Medicine (DL Medicine) has a strategic partnership with HitGen Ltd around accessing and integrating HitGen's DNA-encoded library (DEL) technology platform of over 150 billion compounds for use against DL Medicine targets. To best utilize HitGen's world leading DEL technology, DL Medicine is developing a proprietary drug discovery platform to identify novel, potent chemical lead matter with excellent drug-like properties as initial starting points for lead development. This platform will be used in screening against both standard druggable targets as well as unconventional (i.e. classical undruggable) targets. DL Medicine will also utilize the DEL platform to aid in the validation of biological pathways through specific target intervention methodologies. By accessing the emerging R&D landscape in China, which consists of strong government support and a rapidly developing market and economy, including a highly professional CRO and CMO industry, DL Medicine is positioned as a resource-efficient discovery operation utilizing the enormous capabilities of the Asia-Pacific biotechnology region.

Team

  • Wei Chen, Ph.D., CEO

    Dr. Chen joined NetVation DL Medicine as the chief executive officer and a member of the board of directors. Prior to joining DL Medicine, he has been leading drug discovery efforts at HitGen Ltd, one of DL Medicine's investors. Dr. Chen has more than 20 years' experience in the Biotech and Pharmaceutical industry (Genome Therapeutics, Millennium, Takeda, HitGen) and has had scientific and management roles in drug discovery. Trained as a biochemist/enzymologist, he has broadened his expertise into molecular cell biology and pharmacology during his postdoctoral work at Harvard University. Dr. Chen has participated and led efforts in all stages of drug discovery, from target identification to IND filing, of which several programs are currently in clinical trials. He also has significant experience in translational medicine research, in particular supporting clinical trial efforts.
  • Steve Faraci, Ph.D., CSO

    Dr. Faraci has more than 25 years' experience in large Pharma and Biotech with expertise in screening, lead discovery, formulation and CMC. Recently, Dr. Faraci was Executive Director and Site Head at Capsugel's Product Development Center with a focus on formulation development and clinical manufacturing. Previously, Dr. Faraci worked for over 22 years at Pfizer Global Research & Development in a variety of leadership roles throughout the organization. He was a founding member of the leadership team that helped build a new R&D site in Cambridge, MA in 1999, growing from 10 employees to over 150. He had various leadership roles at the site, including Head of Biology, Interim Site Head and Chief Operating Officer. His responsibilities included internal research and development as well as external academic/industry collaborations. Steve was a member of the Mass Biotech Council Board of Directors. He received his Ph.D. in Chemistry from Wesleyan University and continued his training as a National Institute of Health Postdoctoral Fellow at the Massachusetts Institute of Technology and Harvard Medical School in the laboratory of Professor Christopher Walsh.
  • Roman Herrera, Ph.D., Senior Advisor

    Dr. Herrera has worked for over 20 years in large Pharma and Biotech, in particular in vitro and in vivo biology in the areas of Metabolic Disease, Inflammation and Oncology. Dr. Herrera obtained his Ph.D. in Molecular Pharmacology at Albert Einstein Medical College studying the structure-function relationship of the insulin receptor. After post-doctoral training at the Dana Farber Cancer Institute, studying genes linked to cell differentiation, he joined Parke-Davis/Warner Lambert-Pfizer (Ann Arbor, MI/Cambridge/MA) where he worked in drug discovery programs across several disease areas such as inflammation, diabetes and cancer. He assumed increased leadership roles in target identification/validation, in vivo disease models and biomarkers strategies to support both pre-clinical and clinical (Phase I/II) programs.

DL Medicine's Scientific Advisors

NetVation DL Medicine has been working with scientific advisors and
collaborators from the Chinese and US academic community

  • Ning Zheng, Ph.D.

    Professor, Howard Hughes Medical Institute and Department of Pharmacology, University of Washington, Seattle, Washington. Expert in E3 ligase, molecular and structural mechanisms by which protein ubiquitination controls eukaryotic biology and human diseases.
  • Chen Dong, Ph.D.

    Professor, Dean of the School of Medicine, Tsinghua University, Beijing, China. Research involves molecular mechanisms whereby immune and inflammatory responses are regulated, and to apply this knowledge to the understanding and treatment of autoimmunity and allergy disorders as well as cancer.

Investors

  • HitGen Ltd

    HitGen is an innovation driven life science company based in Chengdu, China and Houston, Texas. HitGen has established a unique platform for early drug discovery research, utilizing DNA encoded libraries containing more than 150 billion novel, diverse drug-like compounds. The library is founded on many hundreds of distinct chemical scaffolds, designed with tractable chemistry and proven results for finding drug leads against targets from known and novel protein classes.
  • AnlongMed Fund

    Anlong Life Sciences Fund (安龙基金) is a Beijing, China based company focused on early-stage investments in the life sciences and healthcare-related fields, such as biotech & pharma, medical devices, life sciences, and medical services.
  • Pfizer

    At Pfizer, we apply science and its global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety and value in the discovery, development and manufacture of health care products. Our global portfolio includes medicines and vaccines as well as many of the world’s best-known consumer health care products. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time.

News and Information

NetVation DL Medicine Announces Research Collaboration with Pfizer Inc.

Chengdu, China Feb, 6th, 2018 NetVation DL Medicine ("DL Medicine"), a privately held biotechnology company based in Chengdu, China, and focused on the discovery and development of novel drug candidates, announced today that it has entered into a two-year research collaboration with Pfizer Inc (NYSE: PFE). Under the terms of the agreement, DL Medicine will screen and collaborate with Pfizer in producing new chemical entities against pre-selected targets from multiple therapeutic areas. As part of the collaboration, Pfizer has taken a financial stake in DL Medicine.

DL Medicine utilizes resources, funding and emerging technologies from the expanding biotechnology capabilities of the growing life sciences industry in China and employs novel approaches to identify and develop new drug candidates. .

Research conducted under this collaboration will utilize HitGen's DNA-encoded libraries to validate early targets, identify novel chemical matter, and conduct lead optimization. . Compounds that meet specific requirements will be advanced further in the discovery process. Additional screening technology platforms will also be utilized..

Dr Wei Chen, CEO of DL Medicine, said: “We are delighted to announce this collaboration with Pfizer, and we look forward to working together to potentially discover new chemical entities for the treatment of diseases that negatively impact the health of patients worldwide.”.

“New target ideas and novel chemical matter are critical to our success in bringing new therapies to patients around the world,” said Yuan-Hua Ding, Executive Director, External Science & Innovation, Pfizer. “This collaboration represents our worldwide commitment to partnering with companies that are doing innovative scientific work to help enhance our portfolio across multiple disease areas.”

About NetVation DL Medicine

DL Medicine is a newly formed discovery stage company dedicated to apply emerging technologies to expedite the drug discovery process, financed by HitGen and Anlong, a healthcare focused fund backed by Chinese Academy of Sciences. In addition, to learn more about NetVation DL Medicine, please visit us on www.ntdlmed.com.

About Pfizer Inc

At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety and value in the discovery, development and manufacture of health care products. Our global portfolio includes medicines and vaccines as well as many of the world's best-known consumer health care products. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as one of the world's premier innovative biopharmaceutical companies, we collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. For more than 150 years, we have worked to make a difference for all who rely on us. We routinely post information that may be important to investors on our website at www.pfizer.com. In addition, to learn more, please visit us on www.pfizer.com and follow us on Twitter at @Pfizer and @Pfizer_News, LinkedIn, YouTube and like us on Facebook at Facebook.com/Pfizer.

Contact Information

NetVation DL Medicine

Website: www.nvdlmed.com
Address: F9 Building B3, Tianfu Life Science Park
     88 South Keyuan Road
     Chengdu, Sichuan 610041, China
Tel: +86-15982870349 FAX: +86-028-85197385
Email: info@nvdlm.com

成都科辉先导医药开发公司

网站:www.nvdlmed.com
地址:中国成都高新区科园南路88号天府生命科技园B3栋9楼,邮编 610041
电话:+86-15982870349 传真:+86-028-85197385
电子邮件:info@nvdlm.com